Alec J. Batts

Alec J. Batts

Auto-generated profile, based on publicly available information

Alec J. Batts

Dept. of Biomedical Engineering, Columbia University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AKAlina R. Kline-Schoder
Alina R. Kline-Schoder
SCSana Chintamen
Sana Chintamen
MWMoshe J. Willner
Moshe J. Willner
MDMelody R. DiBenedetto
Melody R. DiBenedetto
RNRebecca L. Noel
Rebecca L. Noel
EKElisa Konofagou
Elisa Konofagou

25 April 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RNRebecca Lynn Noel
Rebecca Lynn Noel
ABA. J. Batts
A. J. Batts
RJR. Ji
R. Ji
Antonios PouliopoulosAntonios Pouliopoulos
Antonios Pouliopoulos
SBS. Bae
S. Bae
EKElisa Konofagou
Elisa Konofagou
Focused Ultrasound (FUS) paired with systemically-injected microbubbles (μB) is capable of transiently opening the blood–brain barrier (BBBO) for noninvasive and targeted drug delivery to the brain. FUS-BBBO is also capable of modulating the neuroimmune system, further qualifying its therapeutic potential for neurodegenerative diseases like Alzheimer’s disease (AD). Natural aging and AD impose significant strain on the brain and particularly the BBB, modifying its structure and subsequently, its functionality. The emerging focus on treating neurodegenerative diseases with FUS-BBBO necessitates an investigation into the extent that age and AD affect the BBB’s response to FUS. FUS-BBBO was performed with a 1.5-MHz, geometrically focused transducer operated at 450 kPa and paired with a bolus microbubble injection of 8 × 108 μB/mL. Here we quantify the BBBO, BBB closing (BBBC) timeline, and BBB permeability (BBBP) following FUS-BBBO in male mice with and without AD pathology, aged 10 weeks, one year, or two years. The data presented herein indicates that natural aging and AD pathology may increase initial BBBO volume by up to 34.4% and 40.7% respectively, extend BBBC timeline by up to 1.3 and 1.5 days respectively, and increase BBBP as measured by average Ktrans values up to 80% and 86.1% respectively in male mice. This characterization of the BBB response to FUS-BBBO with age and AD further clarifies the nature and extent of the functional impact of these factors and may offer new considerations for planning FUS-BBBO interventions in aged and AD populations.

18 March 2022 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
ABAlec J. Batts
Alec J. Batts
RJRobin Ji
Robin Ji
AKAlina R. Kline-Schoder
Alina R. Kline-Schoder
RNRebecca L. Noel
Rebecca L. Noel
EKElisa Konofagou
Elisa Konofagou
Focused ultrasound (FUS) for blood-brain barrier (BBB) opening is a safe, reversible and non-invasive strategy for targeted drug delivery to the brain, however extensive pre-planning strategies are necessary for successful FUS-mediated BBB opening through the structurally complex primate skull. Objective: This study aims to demonstrate a pre-planning pipeline consisting of transcranial simulations and in vitro experimentation used to inform synchronous BBB opening and power cavitation imaging (PCI) with a single theranostic ultrasound (TUS) phased array. Methods: Acoustic wave propagation simulation findings of pressure attenuation and focal shift through clinical-CT and micro-CT-based primate skull models were compared, while the latter were used to determine the impact of beam steering angle on focal shift and pressure attenuation. In vitro experimentation with a channel phantom enabled characterization of skull-induced receive focal shift (RFS), while in vivo BBB opening and PCI using in silico and in vitro pre-planning information was conducted using a custom Verasonics/MATLAB script. Results: Simulations confirmed steering angle dependent transcranial focal shift and pressure attenuation, while in vitro experiments revealed minimal (0.30-1.50 mm) skull-induced RFS. In vivo rodent experiments with overlaid primate skull fragments demonstrated successful TUS-mediated BBB opening and spatially correlated power cavitation images (PCI) with regions of BBB opening on T 1 -weighted magnetic resonance images (MRI). Conclusion: We demonstrated the feasibility for TUS-mediated BBB opening in vivo using in silico and in vitro pre-planning information. Significance: TUS as an ultrasound-guided modality for BBB opening could serve as a promising alternative to current FUS-mediated BBB opening configurations in the clinic.

9 October 2025 in Brain Stimulation
Verified
Journal Article
Open access
ABAlec J. Batts
Alec J. Batts
FTFotios Tsitsos
Fotios Tsitsos
JIJeannette Ingabire
Jeannette Ingabire
GDGuillaume Duret
Guillaume Duret
SGSamantha L. Gorman
Samantha L. Gorman
EKElisa Konofagou
Elisa Konofagou
Brain stimulation techniques are critical for unraveling the innerworkings of complex neuronal pathways governing both normal physiological function and pathologic states in neurological disorders. Focused ultrasound (FUS) is an emerging technique poised to significantly alter central nervous system (CNS) drug delivery and neuroscience research through non-invasive means. Magnetogenetics is a brain stimulation technique which may benefit from FUS technology in that alternating magnetic fields (AMF), like FUS , can pass through the skull without requiring surgery. Magnetogenetics involves the deposition of superparamagnetic iron-oxide nanoparticles (SPIONs) and overexpression of thermoreceptor transmembrane proteins (e.g. TRPV1 and TRPA1) in the brain. When an external AMF is applied, SPIONs generate local heating, which can activate thermoreceptors, depolarize the cell membrane and trigger action potentials in neurons. Monitoring neuronal activation by magnetogenetics approach can be facilitated by the co-expression of genetically-encoded voltage indicators (GEVI), which enable fluorescence-based detection of membrane depolarization. However, traditional surgical methods used to introduce these components into the brain are invasive and highly focal, precluding investigation of brain-wide neuronal pathways. Here, we demonstrate that our recently developed, flexible configuration for FUS therapy and ultrasound imaging, called theranostic ultrasound (ThUS), can transiently open the blood-brain barrier (BBB) and facilitate the non-invasive delivery of SPION and viral vectors encoding thermoreceptors and GEVI, to enable remote magnetogenetic modulation. We also report significant advances in ThUS pulse sequence design, where we developed a novel multi-target opening volume expansion (MOVE) pulse sequence to maximize BBB opening volume within a single ThUS treatment. ThUS MOVE yielded increased gene delivery commensurate with the number of targeted focal zones and achieved brain-wide expression of GEVI. The results presented herein not only demonstrate the feasibility for ThUS to facilitate a non-invasive brain stimulation approach, but also showcase a method for eliciting larger volumes of BBB opening within a single sonication which could dramatically improve gene delivery procedures for both preclinical research and therapeutic purposes in the future.

24 December 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SBSua Bae
Sua Bae
KLKeyu Liu
Keyu Liu
Antonios PouliopoulosAntonios Pouliopoulos
Antonios Pouliopoulos
RJRobin Ji
Robin Ji
SJSergio Jiménez-Gambín
Sergio Jiménez-Gambín
EKElisa Konofagou
Elisa Konofagou
Background: Focused ultrasound (FUS) in combination with microbubbles has recently shown great promise in facilitating blood-brain barrier (BBB) opening for drug delivery and immunotherapy in Alzheimer’s disease (AD). However, it is currently limited to systems integrated within the MRI suites or requiring post-surgical implants, thus restricting its widespread clinical adoption. In this pilot study, we investigate the clinical safety and feasibility of a portable, non-invasive neuronavigation-guided FUS (NgFUS) system with integrated real-time 2-D microbubble cavitation mapping. Methods: A phase 1 clinical study with mild to moderate AD patients (N=6) underwent a single session of microbubble-mediated NgFUS to induce transient BBB opening (BBBO). Microbubble activity under FUS was monitored with real-time 2-D cavitation maps and dosing to ensure the efficacy and safety of the NgFUS treatment. Post-operative MRI was used for BBB opening and closure confirmation as well as safety assessment. Changes in AD biomarker levels in both blood serum and extracellular vesicles (EVs) were evaluated, while changes in amyloid-beta (Aβ) load in the brain were assessed through 18 F-Florbetapir PET. Results: BBBO was achieved in 5 out of 6 subjects with an average volume of 983±626 mm 3 following FUS at the right frontal lobe both in white and gray matter regions. The outpatient treatment was completed within 34.8±10.7 min. Cavitation dose significantly correlated with the BBBO volume ( R 2 >0.9, N =4), demonstrating the portable NgFUS system’s capability of predicting opening volumes. The cavitation maps co-localized closely with the BBBO location, representing the first report of real-time transcranial 2-D cavitation mapping in the human brain. Larger opening volumes correlated with increased levels of AD biomarkers, including Aβ42 ( R 2 =0.74), Tau ( R 2 =0.95), and P-Tau181 ( R 2 =0.86), assayed in serum-derived EVs sampled 3 days after FUS ( N =5). From PET scans, subjects showed a lower Aβ load increase in the treated frontal lobe region compared to the contralateral region. Reduction in asymmetry standardized uptake value ratios (SUVR) correlated with the cavitation dose ( R 2 >0.9, N =3). Clinical changes in the mini-mental state examination over 6 months were within the expected range of cognitive decline with no additional changes observed as a result of FUS. Conclusion: We showed the safety and feasibility of this cost-effective and time-efficient portable NgFUS treatment for BBBO in AD patients with the first demonstration of real-time 2-D cavitation mapping. The cavitation dose correlated with BBBO volume, a slowed increase in pathology, and serum detection of AD proteins. Our study highlights the potential for accessible FUS treatment in AD, with or without drug delivery.

3 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ABAlec J. Batts
Alec J. Batts
RJRobin Ji
Robin Ji
SBSua Bae
Sua Bae
FTFotios Tsitsos
Fotios Tsitsos
SJSergio Jiménez-Gambín
Sergio Jiménez-Gambín
EKElisa Konofagou
Elisa Konofagou
Gene therapy for neurodegenerative diseases faces significant challenges due to the blood-brain barrier (BBB), which limits drug delivery to the central nervous system (CNS). While clinical trials for Parkinson’s disease (PD) have progressed, administration of vectors expressing enzymatic or neurotrophic factor transgenes have required extensive optimization of the delivery method to achieve potentially therapeutic levels of transgene expression. Focused ultrasound (FUS) combined with microbubbles has emerged as a promising non-invasive strategy to transiently open the BBB for targeted gene delivery via viral nanocarriers including recombinant adeno-associated viruses (AAVs). However, key factors influencing FUS-mediated AAV delivery, including dose distribution and therapeutic efficacy, remain underexplored in non-human primates (NHPs). Here, we evaluated the feasibility of AAV9-CAG-GFP delivery using two portable therapeutic ultrasound modalities: ultrasound-guided, spherically-focused FUS (USgFUS) and a novel low-frequency linear array configuration for imaging and therapy called theranostic ultrasound (ThUS). In mice, FUS-sonicated regions exhibited a 25-fold increase in AAV9 biodistribution compared to systemic injection alone. Extending this approach to NHPs, we observed up to a 200-fold increase in AAV9 DNA in treated brain regions, including PD-relevant structures. In assessing the translational therapeutic potential of this technique, ThUS-mediated AAV9-hSyn-hNTRN (human neurturin) delivery in a toxin mouse model of PD facilitated the rescue of up to 80% and 75% of degenerated dopaminergic neurons in the substantia nigra and striatum, respectively. These findings demonstrate that portable ultrasound technologies can non-invasively enhance AAV9 delivery to targeted brain regions in both mice and NHPs relative to what can be achieved with intravenous (IV) delivery of the same capsid alone. With further development, these approaches may offer a clinically viable, non-invasive alternative for gene therapy in neurodegenerative diseases. One sentence summary: BBB opening with portable therapeutic ultrasound non-invasively increased viral gene delivery to the brain after systemic AAV vector administration in mice and rhesus macaques.